PART I Company Overview We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, dev...
Q2 FY2026 — expected 2026-08-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001724521-26-000009 | EDGAR | 79K words |
| 2025-02-25 | 2024-12-31 | 0001724521-25-000040 | EDGAR | — |
| 2024-02-21 | 2023-12-31 | 0001724521-24-000052 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005112 | EDGAR | — |
| 2022-02-23 | 2021-12-31 | 0000950170-22-001788 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008270 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0001564590-20-008972 | EDGAR | — |
| 2019-03-05 | 2018-12-31 | 0001564590-19-006274 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-28 | 2025-09-30 | 0001724521-25-000116 | EDGAR | 45K words |
| 2025-08-06 | 2025-06-30 | 0001724521-25-000101 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0001724521-25-000063 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001724521-24-000160 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001724521-24-000138 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001724521-24-000092 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001724521-23-000021 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0000950170-23-038760 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019695 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0000950170-22-021241 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0000950170-22-014280 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008502 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001724521-26-000014 | EDGAR | 1K words |
| 2026-02-25 | 0001724521-26-000007 | EDGAR | — |
| 2025-12-18 | 0001724521-25-000122 | EDGAR | — |
| 2025-12-12 | 0001724521-25-000120 | EDGAR | — |
| 2025-11-03 | 0001193125-25-262589 | EDGAR | — |
| 2025-10-28 | 0001724521-25-000114 | EDGAR | — |
| 2025-10-14 | 0001724521-25-000109 | EDGAR | — |
| 2025-10-06 | 0001724521-25-000107 | EDGAR | — |
| 2025-08-06 | 0001724521-25-000099 | EDGAR | — |
| 2025-06-12 | 0001724521-25-000078 | EDGAR | — |
139 total filings indexed. 109 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001724521 |
| Ticker | RCUS |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.arcusbio.com |
| Listed | 2018-03-15 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report